Skip to content

Earnings call

Acutaas Chemicals Q2 FY25 earnings call: AMI Organics' revenue growth guidance for FY25 was revised upwards from 25% to 30%, based on orders in hand and the forecast

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

AMI Organics' revenue growth guidance for FY25 was revised upwards from 25% to 30%, based on orders in hand and the forecast. AMI Organics started civil structure work and ordered machinery for the electrode additive CAPEX project; construction is expected to start soon and completion is hoped for in H1 of Calendar Year 25. AMI Organics delivered 43.2% year-on-year revenue growth in Q2 FY25, driven by pharmaceutical intermediates and Specialty Chemical business. AMI Organics' CAPEX for H1 FY25 was 80 crore, mainly for remaining CAPEX at the Ankleshwar site and some for solar and electrolyte additive CAPEX.

The numbers management gave

Results

  • AMI Organics delivered 43.2% year-on-year revenue growth in Q2 FY25, driven by pharmaceutical intermediates and Specialty Chemical business.
    Show source
    Coming to the performance of AMI Organics: Even in this difficult industry backdrop, I am delighted to share that we have been able to deliver a stellar revenue growth of 43.2% year-on-year in Q2 FY25.
  • The Pharmaceutical Intermediate business grew 53% year-on-year in Q2 FY25, driven by strong performance in key molecules and an earlier-than-anticipated ramp-up in CDMO business.
    Show source
    Let me elaborate more on the business performance: Starting with the Pharmaceutical Intermediate business: The Pharmaceutical Intermediate business grew strongly by 53% Y-o-Y in Q2 FY25.
  • Specialty Chemicals grew 7.6% year-on-year in Q2 FY25, mainly because of subpar performance in subsidiary Baba Fine Chem; excluding Baba Fine Chem, Specialty Chemical business grew more than 25%, offset by de-growth in BFC.
    Show source
    In Specialty Chemicals we deliver growth of 7.6% Y-o-Y, I would like to highlight here that, this was mainly driven by subpar performance in our subsidiary, Baba Fine Chem, if we look at the business ex-Baba Fine Chem, then there was a more than 25% growth in the Specialty Chemical business, which was offset by de-growth in BFC.
  • AMI Organics' revenue from operation was 246.7 crore in Q2 FY25, up 43.2% year-on-year.
    Show source
    I will start with the Quarterly Performance: Revenue from operation for the quarter reached 246.7 crore representing 43.2% increase year- on-year basis.
  • AMI Organics' gross profit was Rs.107.2 crore in Q2 FY25, up 51.5% compared to the same period last year.
    Show source
    Gross profit for the quarter was Rs.107.2 crore, reflecting 51.5% increase compared to the same period last year.
  • AMI Organics' gross margin was 43.4% in Q2 FY25, up 239 basis point year-on-year and 136 basis point quarter-on-quarter, driven by better product mix.
    Show source
    The gross margin was 43.4% up to 239 basis point on year-on-year basis, and 136 basis point on Q-on-Q basis.
Show 11 more statements

Results

  • AMI Organics' EBITDA was Rs.48.9 crore in Q2 FY25, almost doubled compared to the same period last year.
    Show source
    EBITDA for the quarter was Rs.48.9 crore, almost doubled compared to the same period last year.
  • AMI Organics' EBITDA margin was 19.8% in Q2 FY25, up 543 basis point year-on-year and 312 basis point quarter-on-quarter, driven by gross margin and operating leverage.
    Show source
    EBITDA margins were at 19.8% up 543 basis point year-on-year basis and 312 basis point Q-on-Q basis.
  • AMI Organics' PAT was Rs.37.6 crore in Q2 FY25, 1.5 times the adjusted PAT of 14.7 crore in Q2 FY24.
    Show source
    PAT for the quarter was Rs.37.6 crore, which grew 1.5 times compared to the adjusted PAT of 14.7 crore in Q2 FY24.
  • AMI Organics' PAT margin was 15.2% in Q2 FY25, expanding 668 basis point year-on-year and 682 basis point quarter-on-quarter.
    Show source
    PAT margins for the quarter was 15.2% so the expansion of 668 basis point Y-o-Y basis, and 682 basis Q-on-Q basis.
  • AMI Organics' revenue from operation was 423.4 crore in H1 FY25, up 29.8% year-on-year.
    Show source
    Moving on the half yearly performance: Revenue from the operation for the first half of the year reach for 423.4 crore representing 29.8% increase on year-on-year basis.
  • AMI Organics' EBITDA was Rs.78.4 crore in H1 FY25, up 33.4% year-on-year.
    Show source
    EBITDA for the H1 FY25 was Rs.78.4 crore, up 33.4% Y-o-Y basis.
  • AMI Organics' PAT was 52.3 crore in H1 FY25, up 41.3% year-on-year.
    Show source
    PAT for H1 FY25 was at 52.3 crore, up 41.3% Y-o-Y basis.
  • AMI Organics' working capital was 108 days during H1 FY25, driven by improved debtor and inventory days.
    Show source
    I am happy to share that even with strong growth we were able to control our working capital, which was 108 days during H1 FY25, this was driven by improved debtor and inventory days.
  • AMI Organics generated 46 crore of cash flow from operation in H1 FY25, equal to 60% of EBITDA, through better working capital management.
    Show source
    Better working capital management lead to strong generation of cash flow from operation of 46 crore, which was 60% of the EBITDA for H1 FY25.

Money and capital

  • AMI Organics' CAPEX for H1 FY25 was 80 crore, mainly for remaining CAPEX at the Ankleshwar site and some for solar and electrolyte additive CAPEX.
    Show source
    Coming to CAPEX for the year, CAPEX for H1 FY25 was 80 crore, majority of this was for remaining CAPEX of Ankleshwar site and some towards solar and electrolyte, additive CAPEX.
  • AMI Organics' net cash and cash equivalent were 279.5 crore in Q2 FY25.
    Show source
    Moving on to the balance sheet item: Net cash and cash equivalent were at 279.5 crore.

What it expects ahead

What management expects

  • AMI Organics' revenue growth guidance for FY25 was revised upwards from 25% to 30%, based on orders in hand and the forecast.
    Show source
    Looking at the orders in our hand and the forecast what we have, we are revising our revenue growth guidance upwards from 25% to 30% for FY25.
  • AMI Organics expects 30 crores to 40 crore revenue from the electrolyte additive in this year, but that may be deferred; its guidance excludes the electrolyte additive.
    Show source
    So, that will be remaining like that, a very few minimal portion of 30 crores to 40 crore revenue we were expecting in this year.

What it is building and selling

Projects and capacity

  • AMI Organics started civil structure work and ordered machinery for the electrode additive CAPEX project; construction is expected to start soon and completion is hoped for in H1 of Calendar Year 25.
    Show source
    Overall, we hope that we will complete the project in H1 of Calendar Year 25.
  • At the Ankleshwar project, one production block was completed and work on the other two blocks was progressing, with completion expected in the current quarter; the work was slightly delayed by extended and heavy rains during Q2.
    Show source
    Remaining work of other two blocks is progressing, and this is expected to be completed in current quarter.
  • Extended heavy rains in Gujarat impacted AMI Organics' solar project work during the monsoon, delaying it; completion is expected by end of Q3 FY25, energy savings are expected to start from Q4 FY25 and contribute positively to EBITDA.
    Show source
    We now expect this project to be completed by end of Q3 FY25, with energy saving expected to start from Q4 FY25 which will contribute positively to our EBITDA.

Demand and pricing

  • Demand for the part of the semiconductor industry served by Baba Fine Chem remains subdued, impacting BFC sales; management expects growth to return in FY26, viewing the situation as temporary.
    Show source
    Page 4 of 19 AMI Organics Limited October 29, 2024 As Naresh mentioned, the demand scenario for the part of semiconductor industry that we are serving remains subdued, which is impacting sales of BFC, but we are very much optimistic that this is a temporary situation and we will soon see growth coming back in FY26.

Segments

  • Management said AMI Organics is strong in anti-cancer, anti-psychotic, anti-depression, anticoagulants and some antiretrovirals, and also in anti-diabetic; its pipeline in these areas is strong.
    Show source
    Krishan Parwani: Couple of questions from my side.

Deals and partners

  • AMI Organics sent product samples to customers in Korea and Japan after starting to promote Baba Fine Chem products in new geographies.
    Show source
    As explained in last conference call as well, we have already started promoting our products of BFC to new geographies, and have already sent samples to the customers in Korea and Japan.

Risks, rules and outside factors

Rules and policy

  • The Pharmaceutical and Medical Device Agency (PMDA) of Japan issued an inspection result declaring the Sachin facility GMP compliant during the last quarter. Replaced by a later filing.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Jason Soans: Sure sir. And just lastly from my side of course our products are driven from the end product. So, just wanted to know, I don't want specific product names as such, because I understand confidentiality will issue. But just wanted to know in terms of therapies, any particular therapy helping us in terms of growth, in terms of our demand for our APIs? Management: We are very strong in anti-cancer, anti-psychotic, anti-depression, anticoagulants and some antiretrovirals, very small amount of antiretroviral. But these are the where we are very, very strong, and our pipe line is also very strong that helping us to move very fast in this area. One is anti-diabetic as well. Page 11 of

    Answer, krishan parwani

    Krishan Parwani: Couple of questions from my side. Firstly, your revised guidance of 30% top line growth in FY25 translate to roughly current quarterly sales ended of 250 crores for the coming quarters as well. So, are you being conservative at providing this guidance? Management: Yes, this is the guidance which we are giving which is based on the forecast and orders are on hand.

    Answer, krishan parwani

    Krishan Parwani: Okay, noted sir. And on the CDMO side, keeping confidentiality in mind. But would it be possible to kind of highlight how many intermediates you would have in your pipeline for phase two and phase three drugs? Management: That numbers are very large in phase two, it's in a double digit and there are some are in phase three, and the larger number is in phase one, then lower in phase two, and very few are in phase three right now, in single digit in phase three. But the numbers are not disclosing because we cannot prove that number, because customer has not disclosed us the status and all. So, it's like coding number going, it's not advisable for us to say the status.

    Answer, krishan parwani

    Krishan Parwani: Understood, but we don't want the names obviously, because you also mentioned in your opening remarks, or probably to one of the earlier participant, that it is attracting the competition. But the number of molecules, probably if, but that's fine we understand it's double digit is also fine for phase two. And on JV, I know it's and you also mentioned that there has been a slight delay in the overall EV value chain. But any update you would like to give on the same because that might take care of the growth beyond let's say FY27 or so, so any update there? Management: See growth as Naresh ji mentioned that we have a strong pipeline for our products till 45, so it's not growth is only depend on this Enchem JV or electrolyte solution business. We have other area of growth as well, but as we earlier mentioned also that we want to invest only in the business when we see the good visibility in place, and then only we will have some investment done. Considering current scenario in EV market in particular in India, because this business is focused on India market only.

    Answer, krishan parwani

    So, we have been little cautious and assessing the situation, and then we will move forward. Management: And particularly this is an OEM for them. It's like a tall manufacturing from themselves. We are not going to do any marketing or something like that. It is just in job work, CMO kind of work for them. So, it is not directly or indirectly impacting on our planning. It's just an additional arm for us, giving us and leverage of selling our VC, FEC also to them that will be additional benefit to us.

    Answer, krishan parwani

    Krishan Parwani: Yes, in fact I meant like additional growth beyond FY27, I understand that you have obviously a lot of other projects that you will be working on, but I was just wondering if there is anything Page 12 of 19 AMI Organics Limited October 29, 2024 but okay, fair fund got it. And lastly, I missed your earlier commentary on the electrolyte additives. I am not sure whether you mentioned, when would they start, when would the revenue start flowing in from the electoral additives? Management: If everything goes well, it can be start immediately as well. So, we are ready with everything for initial supplies. So, now we already supplied them the validation quantity at a large commercial scale. Now we are waiting for them to move ahead for placing an order which is a part of the contract, but that is all depends on how fast they will move ahead for their approval and final manufacturing.

    Answer, krishan parwani

    So, it will be very soon, as soon as possible, maybe in Q4, maybe in Q3 as well. But you know very well that we are always, our guidelines and guidance are always excluded from the electrolyte additive. So, that will be remaining like that, a very few minimal portion of 30 crores to 40 crore revenue we were expecting in this year. So, that may defer but it is not clear as of now.

Questions about this call

When was the Acutaas Chemicals Q2 FY25 earnings call transcript filed?
Acutaas Chemicals filed the transcript with the exchange on 5 Nov 2024. This page is built from that transcript.
What does this page list?
26 statements from the transcript across 8 topics, 20 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 1 question and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Acutaas Chemicals Q2 FY25 concall: AMI Organics' revenue growth guidance for FY25 was revised upwards from 25% to 30%, based on orders in hand and the forecast · DalalOS